RT Journal Article
SR Electronic
T1 Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.13.24318504
DO 10.1101/2024.12.13.24318504
A1 Mazziotta, Francesco
A1 Martin, Lauren E.
A1 Eagan, Daniel N.
A1 Bar, Merav
A1 Kinsella, Sinéad
A1 Paulson, Kelly G.
A1 Voillet, Valentin
A1 Lahman, Miranda C.
A1 Hunter, Daniel
A1 Schmitt, Thomas M.
A1 Duerkopp, Natalie
A1 Yeung, Cecilia
A1 Tang, Tzu-Hao
A1 Gottardo, Raphael
A1 Asano, Yuta
A1 Wilcox, Elise C.
A1 Lee, Bo
A1 Zhang, Tianzi
A1 Lopedote, Paolo
A1 Penter, Livius
A1 Wu, Catherine J
A1 Milano, Filippo
A1 Greenberg, Philip D.
A1 Chapuis, Aude G.
YR 2024
UL http://medrxiv.org/content/early/2024/12/16/2024.12.13.24318504.abstract
AB Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was prevented by post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8+ T cells engineered to express a high-affinity Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (TTCR- C4). However, in the present study, infusion of EBV- or Cytomegalovirus (CMV)-specific TTCR-C4 did not clearly improve outcomes in fifteen patients with active disease post-HCT. TCRC4-transduced EBV-specific T cells persisted longer post-transfer than CMV-specific T cells. Persisting TTCR-C4 skewed towards dysfunctional natural killer-like terminal differentiation, distinct from the dominant exhaustion programs reported for T-cell therapies targeting solid tumors. In one patient with active AML post-HCT, a sustained TTCR-C4 effector-memory profile correlated with long-term TTCR-C4 persistence and disease control. These findings reveal complex mechanisms underlying AML-induced T-cell dysfunction, informing future therapeutic strategies for addressing post-HCT relapse.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01640301Funding StatementThis study was funded by grant no. P01CA18029-41 (P.D.G.), grant no. NIH-5K08CA169485 (A.G.C.), the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Research Center (A.G.C.), Damon Runyon (A.G.C.), the Guillot Family ZachAttacksLeukemia Foundation, Parker Institute for Cancer Immunotherapy (P.D.G.), Gabrielle s Angel Foundation, the V Foundation, and Juno Therapeutics. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Fred Hutchinson Cancer Center (FHCC) Institutional Review Board, the US Food and Drug Administration and the National Institutes of Health Recombinant DNA Advisory Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data will be deposited and made publicly available after peer-reviewed publication